ConvaTec Group (LON:CTEC) Shares Down 1.3% – Here’s What Happened

by · The Cerbat Gem

ConvaTec Group PLC (LON:CTEC – Get Free Report) shares traded down 1.3% during trading on Tuesday . The company traded as low as GBX 238.60 and last traded at GBX 238.60. 3,496,931 shares were traded during mid-day trading, a decline of 81% from the average session volume of 18,504,021 shares. The stock had previously closed at GBX 241.80.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. UBS Group restated a “buy” rating and set a GBX 375 target price on shares of ConvaTec Group in a research report on Friday, November 7th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of ConvaTec Group in a research report on Friday, November 14th. Finally, Peel Hunt reissued an “add” rating and set a GBX 270 price objective on shares of ConvaTec Group in a report on Thursday, November 13th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat.com, ConvaTec Group presently has a consensus rating of “Buy” and an average price target of GBX 318.67.

Get Our Latest Research Report on CTEC

ConvaTec Group Price Performance

The company has a debt-to-equity ratio of 85.32, a quick ratio of 0.96 and a current ratio of 2.26. The company has a 50-day moving average price of GBX 237.72 and a 200-day moving average price of GBX 244.36. The firm has a market capitalization of £4.67 billion, a P/E ratio of 22.51, a price-to-earnings-growth ratio of 0.93 and a beta of 0.64.

About ConvaTec Group

(Get Free Report)

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.

Further Reading